Mont-Saint-Guibert, Belgium, - The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation for 2013 edition of the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14, 2013.
After a successful participation in 2012, Cardio3 will have another opportunity to present an overview of the Company’s strategy and key development programs to multiple US institutional investors.
Dr Christian Homsy, CEO of Cardio3 BioSciences, commented: “We are glad to be able to present at this KBC seminar in New York. This is an excellent opportunity for us to continue to build the C3BS profile, as one of the world leaders in the field of regenerative medicine, with US investors. As a newly listed company we will continue to have a pro-active IR program in order to keep our current shareholders well informed and to broaden our potential shareholder base.”